With the international controversy surrounding hydroquinone and the proposed ban tabled by the FDA, the need for a safe and effective skin brightener is pressing. Lumixyl™ was developed by dermatological researchers at Stanford University to target pigmentation efficiently and without the side effects of hydroquinone and other alternatives.

A synthetic peptide, Lumixyl is the first science-based innovation in skin brightening in two decades. In this webcast, the product’s inventor Dr. Basil Hantash will review for you the science behind this innovation and its clinical applications. Participants will walk away from this webcast with a technical understanding of the Lumixyl cream and an appreciation of its functional merits in the improvement of hyperpigmentation.

Dr. Hantash has been part of the founding team of 8 medical device or biotech start-ups, accumulating a decade of operational experience and over 17 years of medical research experience in the life science industry. His efforts have led to 2 acquisitions, over a dozen FDA-approvals, more than 40 patents, and some 75 peer-reviewed publications. Dr. Hantash completed his dermatology residency, postdoctoral training in the Program for Regenerative Medicine, and a prestigious fellowship in the Biodesign Innovation Program at Stanford University. He received his MD and PhD (pharmacology and physiology) from New Jersey Medical School, where he was inducted in the AOA Medical Honor Society and graduated as valedictorian of both his Graduate and Medical School. Dr. Hantash received his BS in Biology and minor in Chemistry from the University of Illinois, where he was the recipient of a Howard Hughes Research Fellowship